![Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-018-0155-7/MediaObjects/41408_2018_155_Fig1_HTML.png)
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal
![5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f29f5c3e-5a9b-447a-8641-63022e061899/gr1_lrg.gif)
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
![A Nomogram Predicting Overall and Cancer-Specific Survival of Patients with Primary Bone Lymphoma: A Large Population-Based Study A Nomogram Predicting Overall and Cancer-Specific Survival of Patients with Primary Bone Lymphoma: A Large Population-Based Study](https://static.hindawi.com/articles/bmri/volume-2020/4235939/figures/4235939.fig.003d.jpg)
A Nomogram Predicting Overall and Cancer-Specific Survival of Patients with Primary Bone Lymphoma: A Large Population-Based Study
![Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer](https://www.mdpi.com/cancers/cancers-11-01239/article_deploy/html/images/cancers-11-01239-g006.png)
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
![Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram](https://www.researchgate.net/publication/328286526/figure/fig2/AS:682002189660161@1539613401325/Overall-survival-curve-by-treatment-method-The-5-year-overall-survival-rate-and-median.png)
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
![Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer](https://www.mdpi.com/cancers/cancers-11-01239/article_deploy/html/images/cancers-11-01239-g004.png)
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
![5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO 5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO](https://www.bjmo.be/app/uploads/2021/11/Banner-KN024-EN-V1-2400x1800-NOV21.jpg)
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
![Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12957-021-02478-x/MediaObjects/12957_2021_2478_Fig1_HTML.png)
Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text
![Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate](https://d2ogjlfjkptkow.cloudfront.net/contentimage/37909.jpg)
Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate
![Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-06738-z/MediaObjects/12885_2020_6738_Fig3_HTML.png)
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
![Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086418309353-gr1.jpg)